Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2017

01-10-2017 | Editorial

Whither surgical quality assurance of breast cancer surgery (surgical margins and local recurrence) after paterson

Authors: N. J. Bundred, J. Thomas, J. M. J. Dixon

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Login to get access

Abstract

Purpose

The Kennedy report into the actions of the disgraced Breast Surgeon, Paterson focussed on issues of informed consent for mastectomy, management of surgical margins and raised concerns about local recurrence rates and the increasing emphasis on cosmesis after mastectomy for breast cancer. This article assesses whether Kennedy’s recommendations apply to the UK as a whole and how to address these issues. New GMC advice on consent and newer nonevidenced innovations in immediate reconstruction have altered the level of informed consent required. Patients deserve a better understanding of the issues of oncological versus cosmetic outcomes on which to base their decisions. Involvement of the whole multidisciplinary team including Oncologists is necessary in surgical planning. Failure to obtain clear microscopic margins at mastectomy leads to an increased local recurrence, yet has received little attention in the UK. Whereas, other countries have used surgical quality assurance audits to reduce local recurrence; local recurrence rates are not available and the extent of variation across the UK in margin involvement after surgery, its management and relationship to local recurrence needs auditing prospectively to reduce unnecessary morbidity. To reassure public, patients and the NHS management, an accreditation system with more rigour than NHSBSP QA and peer review is now required. Resource and efforts to support its introduction will be necessary from the Royal College of Surgeons and the Association of Breast Surgeons. New innovations require careful evaluation before their backdoor introduction to the NHS. Private Hospitals need to have the same standards imposed.
Literature
1.
go back to reference Kennedy Report. Review of the response of Heart of England NHS Foundation Trust to concerns about Mr I Paterson’s Surgical Practice: lessons to be learned and recommendations Kennedy Report. Review of the response of Heart of England NHS Foundation Trust to concerns about Mr I Paterson’s Surgical Practice: lessons to be learned and recommendations
2.
go back to reference Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2014) Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135. doi:10.1016/S0140-6736(14)60488-8 CrossRef Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2014) Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135. doi:10.​1016/​S0140-6736(14)60488-8 CrossRef
3.
go back to reference Al-Himdani S, Timbrell S, Tan KT, Morris J, Bundred N (2016) Prediction of margin involvement and local recurrence after skin-sparing and simple mastectomy. Eur J Surg Oncol 42:935–941CrossRef Al-Himdani S, Timbrell S, Tan KT, Morris J, Bundred N (2016) Prediction of margin involvement and local recurrence after skin-sparing and simple mastectomy. Eur J Surg Oncol 42:935–941CrossRef
4.
go back to reference Fitzsullivan E, Lari SA, Smith B, Caudle AS, Lucci S, Krishnamurthy A et al (2013) Incidence and consequence of close margins in patients with DCIS treated with mastectomy. Is further therapy warranted? Ann Surg Oncol 20:4103–4112CrossRef Fitzsullivan E, Lari SA, Smith B, Caudle AS, Lucci S, Krishnamurthy A et al (2013) Incidence and consequence of close margins in patients with DCIS treated with mastectomy. Is further therapy warranted? Ann Surg Oncol 20:4103–4112CrossRef
5.
go back to reference Timbrell S, Al-Himdani S, Shaw O, Tan K, Morris J, Bundred N (2017) Comparison of local recurrence after simple and SSM in patients with DCIS. Ann Surg Oncol 24(4):1071–1107CrossRef Timbrell S, Al-Himdani S, Shaw O, Tan K, Morris J, Bundred N (2017) Comparison of local recurrence after simple and SSM in patients with DCIS. Ann Surg Oncol 24(4):1071–1107CrossRef
6.
go back to reference Choong LP, Taib NA, Rampal S, Saad M, Bustam AZ, Yip CH (2010) High tumour stage and margin clearance are still important prognostic factors for post-mastectomy locoregional recurrence in Malaysia. Asian Pac J Cancer Prev 11:1409–1416PubMed Choong LP, Taib NA, Rampal S, Saad M, Bustam AZ, Yip CH (2010) High tumour stage and margin clearance are still important prognostic factors for post-mastectomy locoregional recurrence in Malaysia. Asian Pac J Cancer Prev 11:1409–1416PubMed
7.
go back to reference Aalders KC, van Bommel A, van Dalen T, Sonke G et al (2016) Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer 63:118–126CrossRef Aalders KC, van Bommel A, van Dalen T, Sonke G et al (2016) Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer 63:118–126CrossRef
8.
go back to reference Van der Heiden-van der Loos M, Siesling S, Wouters M, van Dalen T et al (2012) The value of ipsilateral breast tumor recurrence as a quality indicator: hospital variation in the Netherlands. Breast Cancer Res Treat 131(2):691–698. doi:10.1007/s10549-011-1809-3 CrossRef Van der Heiden-van der Loos M, Siesling S, Wouters M, van Dalen T et al (2012) The value of ipsilateral breast tumor recurrence as a quality indicator: hospital variation in the Netherlands. Breast Cancer Res Treat 131(2):691–698. doi:10.​1007/​s10549-011-1809-3 CrossRef
9.
go back to reference Thomas J, Hanby A, Pinder S, Ball G, Lawrence G, Maxwell A et al (2014) Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. Eur J Cancer 50:1880–1889CrossRef Thomas J, Hanby A, Pinder S, Ball G, Lawrence G, Maxwell A et al (2014) Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. Eur J Cancer 50:1880–1889CrossRef
10.
go back to reference Schnabel F, Boolbol SK, Gittleman M, Karni T, Tafra L, Feldman S et al (2014) A randomized prospective study of lumpectomy margin assessment with use of margin probe in patients with nonpalpable breast malignancies. Ann Surg Oncol 21:1589–1595CrossRef Schnabel F, Boolbol SK, Gittleman M, Karni T, Tafra L, Feldman S et al (2014) A randomized prospective study of lumpectomy margin assessment with use of margin probe in patients with nonpalpable breast malignancies. Ann Surg Oncol 21:1589–1595CrossRef
11.
go back to reference Association of Breast Surgery at BASO (2009) Surgical guidelines for the management of breast cancer. Eur J Surg Oncol. EJSO. 1:1–22 Association of Breast Surgery at BASO (2009) Surgical guidelines for the management of breast cancer. Eur J Surg Oncol. EJSO. 1:1–22
12.
go back to reference Ellis IO, Al-Sam S, Anderson N et al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. 2016. The Royal College of Pathologists Ellis IO, Al-Sam S, Anderson N et al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. 2016. The Royal College of Pathologists
Metadata
Title
Whither surgical quality assurance of breast cancer surgery (surgical margins and local recurrence) after paterson
Authors
N. J. Bundred
J. Thomas
J. M. J. Dixon
Publication date
01-10-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4369-3

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue

Rebuttal Letter

Response Letter

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine